U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07200622) titled 'Oral Semaglutide in Patients With Alzheimer's Disease' on Sept. 18.
Brief Summary: Alzheimer's disease (AD) is a progressive neurodegenerative disease and a major global healthcare burden. Currently, the disease is only treated symptomatically and an effective disease-modifying therapy (DMT) that may slow the disease progression, and prevent cognitive and functional deterioration, is yet to emerge. Glucagon-like peptide-1 (GLP-1) analogues are being studied to treat neurodegenerative diseases, due to evidence of their neuroprotective effects in mouse models of AD. This study investigates Semaglutide, a modified human GLP-1RA in Alzhe...